Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557148237> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2557148237 abstract "Abstract Abstract 4658 Introduction ITP management has changed since thrombopoietin receptor agonists (TRAs) were approved for its treatment. Current TRAs are recommended for adults at risk of bleeding who relapse after splenectomy, as well as for those where splenectomy is contraindicated and where, at least, one other therapy has failed. The goal of this paper is to present the results of the treatment and follow-up of 21 patients treated with Eltrombopag in our Centre during the last year. Patients We present 21 patients diagnosed with chronic ITP according to the American Society of Hematology guidelines. 7 of them were males and 14 females. The median age was 70 years (range from 26 to 81 years). Previous splenectomy was undergone in 3 patients. 10 patients had previously received two or more therapies for ITP. 11 patients received TRAs as second line treatment. Results On average, platelet counts at the beginning of the treatment with Eltrombopag were 23.000/μL. All patients started with the same doses (50 mg) except one of them who started with 25 mg. Patients only received concurrent ITP therapy (corticosteroids and intravenous immunoglobulins) when platelet counts were under 20,000/μL or bleeding occurred. 8 patients needed rescue medications throughout the treatment with Eltrombopag (7 of them only once). Eltrombopag was withdrawn in a total number of 8 patients due to different reasons: 4 patients were considered as non-responders (3 of them didn't achieve a certain platelet count to prevent major bleeding and, in the fourth one, reducing or suspending the concurrent ITP therapy was not possible. One of these non-responders received Romiplostin and a good response was achieved). In one patient, the therapy was withdrawn due to liver toxicity and in another one, at patient's request. Finally, Eltrombopag was withdrawn in 2 patients because a sustained platelet counts was held. Conclusion TRAs are safe, effective and well-tolerated for those patients who relapse after splenectomy or when splenectomy is contraindicated. In our experience, TRAs could be also useful in other diseases like HCV or HIV associated thrombocytopenia. Eltrombopag and Romiplostin bind in different places to the TPO receptor (TPO-R). This circumstance, together with the different activation pathways, may explain that some non-responders to Eltrombopag could respond to Romiplostin and viceversa. Disclosures: No relevant conflicts of interest to declare." @default.
- W2557148237 created "2016-11-30" @default.
- W2557148237 creator A5008152130 @default.
- W2557148237 creator A5035393613 @default.
- W2557148237 creator A5046020125 @default.
- W2557148237 creator A5047288670 @default.
- W2557148237 creator A5064101081 @default.
- W2557148237 creator A5072676074 @default.
- W2557148237 creator A5079286125 @default.
- W2557148237 date "2012-11-16" @default.
- W2557148237 modified "2023-09-27" @default.
- W2557148237 title "Thrombopoietin Receptor Agonist (ELTROMBOPAG) for Chronic Immune Thrombocytopenic Purpura (ITP) Treatment: 21 Patients in Only One Center" @default.
- W2557148237 doi "https://doi.org/10.1182/blood.v120.21.4658.4658" @default.
- W2557148237 hasPublicationYear "2012" @default.
- W2557148237 type Work @default.
- W2557148237 sameAs 2557148237 @default.
- W2557148237 citedByCount "0" @default.
- W2557148237 crossrefType "journal-article" @default.
- W2557148237 hasAuthorship W2557148237A5008152130 @default.
- W2557148237 hasAuthorship W2557148237A5035393613 @default.
- W2557148237 hasAuthorship W2557148237A5046020125 @default.
- W2557148237 hasAuthorship W2557148237A5047288670 @default.
- W2557148237 hasAuthorship W2557148237A5064101081 @default.
- W2557148237 hasAuthorship W2557148237A5072676074 @default.
- W2557148237 hasAuthorship W2557148237A5079286125 @default.
- W2557148237 hasConcept C109159458 @default.
- W2557148237 hasConcept C126322002 @default.
- W2557148237 hasConcept C141071460 @default.
- W2557148237 hasConcept C2776309230 @default.
- W2557148237 hasConcept C2776915898 @default.
- W2557148237 hasConcept C2777863708 @default.
- W2557148237 hasConcept C2778713057 @default.
- W2557148237 hasConcept C2779771385 @default.
- W2557148237 hasConcept C2780588981 @default.
- W2557148237 hasConcept C2780931953 @default.
- W2557148237 hasConcept C28328180 @default.
- W2557148237 hasConcept C2993327898 @default.
- W2557148237 hasConcept C54355233 @default.
- W2557148237 hasConcept C71924100 @default.
- W2557148237 hasConcept C86803240 @default.
- W2557148237 hasConcept C89560881 @default.
- W2557148237 hasConcept C90924648 @default.
- W2557148237 hasConceptScore W2557148237C109159458 @default.
- W2557148237 hasConceptScore W2557148237C126322002 @default.
- W2557148237 hasConceptScore W2557148237C141071460 @default.
- W2557148237 hasConceptScore W2557148237C2776309230 @default.
- W2557148237 hasConceptScore W2557148237C2776915898 @default.
- W2557148237 hasConceptScore W2557148237C2777863708 @default.
- W2557148237 hasConceptScore W2557148237C2778713057 @default.
- W2557148237 hasConceptScore W2557148237C2779771385 @default.
- W2557148237 hasConceptScore W2557148237C2780588981 @default.
- W2557148237 hasConceptScore W2557148237C2780931953 @default.
- W2557148237 hasConceptScore W2557148237C28328180 @default.
- W2557148237 hasConceptScore W2557148237C2993327898 @default.
- W2557148237 hasConceptScore W2557148237C54355233 @default.
- W2557148237 hasConceptScore W2557148237C71924100 @default.
- W2557148237 hasConceptScore W2557148237C86803240 @default.
- W2557148237 hasConceptScore W2557148237C89560881 @default.
- W2557148237 hasConceptScore W2557148237C90924648 @default.
- W2557148237 hasLocation W25571482371 @default.
- W2557148237 hasOpenAccess W2557148237 @default.
- W2557148237 hasPrimaryLocation W25571482371 @default.
- W2557148237 hasRelatedWork W1191416474 @default.
- W2557148237 hasRelatedWork W1763430791 @default.
- W2557148237 hasRelatedWork W2062664710 @default.
- W2557148237 hasRelatedWork W2116694792 @default.
- W2557148237 hasRelatedWork W2188801772 @default.
- W2557148237 hasRelatedWork W2274268281 @default.
- W2557148237 hasRelatedWork W2409281764 @default.
- W2557148237 hasRelatedWork W2568409640 @default.
- W2557148237 hasRelatedWork W2603751976 @default.
- W2557148237 hasRelatedWork W2735774524 @default.
- W2557148237 hasRelatedWork W2784365942 @default.
- W2557148237 hasRelatedWork W2790396477 @default.
- W2557148237 hasRelatedWork W2955637888 @default.
- W2557148237 hasRelatedWork W3035955857 @default.
- W2557148237 hasRelatedWork W3084109710 @default.
- W2557148237 hasRelatedWork W3086204349 @default.
- W2557148237 hasRelatedWork W3206222204 @default.
- W2557148237 hasRelatedWork W3208918187 @default.
- W2557148237 hasRelatedWork W1682246571 @default.
- W2557148237 hasRelatedWork W3119476135 @default.
- W2557148237 isParatext "false" @default.
- W2557148237 isRetracted "false" @default.
- W2557148237 magId "2557148237" @default.
- W2557148237 workType "article" @default.